经济观察网 康沣生物-B近期股价下跌主要与股本稀释、持续亏损、技术面承压及行业竞争等因素相 关。 股票近期走势 康沣生物-B近期股价出现下跌，例如在2月13日单日下跌3.41%。 资金面与技术面 公司于2026年1月30日完成认购协议A，以每股5.36港元向特定投资者发行559.5万股新股，募集资金净 额约2973万港元，该等股份占扩大后总股本约2.29%。此举虽为业务扩张提供资金，但短期内可能引发 市场对每股收益摊薄的担忧。截至2月13日，股价为5.95港元，低于20日均线及30日均线，MACD柱状 图为负值，显示短期趋势偏弱。当日换手率仅0.02%，区间振幅收窄，反映资金参与度低，流动性不足 可能放大价格波动。 业绩经营情况 公司仍处于投入期，2025年中报显示归母净亏损2381.7万元，净利率为-53.26%。高费用占比进一步凸 显盈利压力。2024年年报显示经营活动现金流净额为-8290.6万元，反映自身造血能力不足。 行业与风险分析 公司主营的微创介入器械领域技术迭代快、研发投入高，且产品商业化进度需时间验证市场接受度。同 期医疗板块表现分化，个股基本面差异导致走势分化。 以上内容基于公开资料整理， ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康灃生物科技（上海）股份有限公司 (「本公司」) (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06922 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 143,438,579 | RMB | | 1 RMB | | 143,438,579 | | 增加 / 減少 (-) | | | 5,595,000 | | | RMB | | 5,595,000 | | 本月底結存 | | | 149,033,579 | RMB | | 1 R ...

康沣生物-B(06922)发布公告，根据于2025年6月20日举行的股东周年大会的一般授权，以认购方式发行 的559.5万股H股。 ...

智通财经APP讯，康沣生物-B(06922)发布公告，根据于2025年6月20日举行的股东周年大会的一般授 权，以认购方式发行的559.5万股H股。 ...

公司名稱： 康灃生物科技(上海)股份有限公司 呈交日期： 2026年1月30日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06922 | 說明 | H股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發 ...

Core Viewpoint - Kangfu Bio-B (06922) has successfully completed the subscription agreement A, issuing a total of 5.595 million shares at a subscription price of HKD 5.36 per share, which represents approximately 3.90% of the H-shares issued prior to the completion of the agreement and about 2.34% of the total issued shares [1] Group 1 - The total amount raised from subscription agreement A is approximately HKD 29.99 million, with a net amount of about HKD 29.73 million after expenses [1] - The net subscription price per share, after deducting all related expenses, is approximately HKD 5.31 [1] - The proceeds from the subscription are intended for research, production, and commercialization of minimally invasive products related to vascular intervention, respiratory intervention, and tumor intervention, as well as potential overseas business expansion for these products [1] Group 2 - Subscription agreement B has been terminated, releasing both parties from their obligations under the agreement without any claims against each other [1] - Following the termination of subscription agreement B, the issuance of the 5.595 million shares under subscription agreement A will result in approximately 3.75% of the H-shares issued after the share allocation and about 2.29% of the total issued shares [1]

Core Viewpoint - 康沣生物-B has successfully completed the subscription agreement A, issuing 5.595 million shares at a price of HKD 5.36 per share, which represents approximately 3.90% of the H-shares issued prior to the completion of the agreement and about 2.34% of the total existing shares [1] Group 1 - The total amount raised from the subscription agreement A is approximately HKD 29.99 million, with a net amount of about HKD 29.73 million after expenses [1] - The net subscription price per share, after deducting all related expenses, is approximately HKD 5.31 [1] - The proceeds from the subscription are intended for research, production, and commercialization of minimally invasive products related to vascular intervention, respiratory intervention, and tumor intervention, as well as potential overseas business expansion for these products [1] Group 2 - The subscription agreement B has been terminated, releasing both parties from their obligations under that agreement without any claims against each other [1]

本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Cryofocus Medtech (Shanghai) Co., Ltd. 康灃生物科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6922） 完成認購協議A 及 終止認購協議B 茲提述康灃生物科技（上海）股份有限公司（「本公司」）日期為2026年1月12日有關 認購事項的公告（「該公告」）。除本公告另有所指外，本公告所用之詞彙與該公告 所界定者具有相同涵義。 完成認購協議A 董事會欣然宣佈，認購協議A的所有條件已獲達成，且認購協議A項下交易已於 2026年1月30日完成。總計5,595,000股認購股份已成功按每股認購股份認購價 5.36港元向認購人A發行及配發。該5,595,000股認購股份相當於(i)緊接認購協議 A完成前已發行H股數目約3.90%及現有已發行股份數目約2.34%；及(ii)緊隨 ...

Core Viewpoint - 康沣生物-B has entered into a subscription agreement to issue a total of 7.46 million H-shares at a price of HKD 5.36 per share, representing a discount of approximately 17.79% from the closing price on the day of the announcement [2] Group 1 - The net proceeds from the subscription are approximately HKD 39.73 million [2] - 80% of the proceeds will be allocated for the research, production, commercialization, and potential overseas expansion of minimally invasive products related to vascular, respiratory, and oncology interventions [2] - The remaining 20% will be used for the company's general working capital [2]

Core Viewpoint - 康沣生物-B (06922) has entered into a subscription agreement to issue a total of 7.46 million H shares at a subscription price of HKD 5.36 per share, representing a discount of approximately 17.79% compared to the closing price of HKD 6.52 on the Hong Kong Stock Exchange on the same day [1] Group 1 - The net proceeds from the subscription are approximately HKD 39.73 million [1] - 80% of the proceeds will be allocated for research, production, and commercialization of minimally invasive interventional products related to vascular intervention, respiratory intervention, and tumor intervention [1] - The remaining 20% of the proceeds will be used for general working capital of the group [1]